Abstract
Cancer therapy is facing the big challenge of destroying selectively tumour cells without harming the normal tissues. Chemotherapy was trying from the beginning to kill malignant cells because of their proliferative activity since normal cells are in general quiescent. Meanwhile side effects were produced due to the destruction of some normal cells that need regular proliferation. The discovery of biomarkers led to the identification of molecular targets within tumour cells in order to kill them selectively. Chemistry followed the progress of biomarkers biotechnology by the production of target specific antagonists which were the subject of many patents. Meanwhile novel problems of tumour resistance appeared and made the battle against cancer a non stop development of new strategies and new weapons. As a consequence, paralleled activities of patenting biomarkers and chemical antagonists are continuously generated. The offer of chemistry does not actually limit the efficiency of Targeted therapy but the identification of biomarkers is still missing the exclusive specificity to tumour cells.
Keywords: Drug approval, neoplasms, cells, drug therapy, combination, drug targeting, efficiency, antagonists and inhibitors, mutation, patients, cell proliferation, proto-oncogene, drug resistance, molecular targeted therapy, united states food and drug administration, screening, target, anti-angiogenic agents
Recent Patents on Biotechnology
Title: The Offer of Chemistry to Targeted Therapy in Cancer
Volume: 5 Issue: 3
Author(s): Ikram Jemel, Karim Jellali, Jihene Elloumi and Sami Aifa
Affiliation:
Keywords: Drug approval, neoplasms, cells, drug therapy, combination, drug targeting, efficiency, antagonists and inhibitors, mutation, patients, cell proliferation, proto-oncogene, drug resistance, molecular targeted therapy, united states food and drug administration, screening, target, anti-angiogenic agents
Abstract: Cancer therapy is facing the big challenge of destroying selectively tumour cells without harming the normal tissues. Chemotherapy was trying from the beginning to kill malignant cells because of their proliferative activity since normal cells are in general quiescent. Meanwhile side effects were produced due to the destruction of some normal cells that need regular proliferation. The discovery of biomarkers led to the identification of molecular targets within tumour cells in order to kill them selectively. Chemistry followed the progress of biomarkers biotechnology by the production of target specific antagonists which were the subject of many patents. Meanwhile novel problems of tumour resistance appeared and made the battle against cancer a non stop development of new strategies and new weapons. As a consequence, paralleled activities of patenting biomarkers and chemical antagonists are continuously generated. The offer of chemistry does not actually limit the efficiency of Targeted therapy but the identification of biomarkers is still missing the exclusive specificity to tumour cells.
Export Options
About this article
Cite this article as:
Jemel Ikram, Jellali Karim, Elloumi Jihene and Aifa Sami, The Offer of Chemistry to Targeted Therapy in Cancer, Recent Patents on Biotechnology 2011; 5 (3) . https://dx.doi.org/10.2174/187220811797579079
DOI https://dx.doi.org/10.2174/187220811797579079 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design Transforming Cancer Epigenetics Using Nutritive Approaches and Noncoding RNAs
Current Cancer Drug Targets Role of α6β4 Integrin in Cell Motility, Invasion and Metastasis of Mammary Tumors
Current Protein & Peptide Science Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy
Mini-Reviews in Medicinal Chemistry Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Quantization of Angiogenesis and Image Analysis
Current Angiogenesis (Discontinued) Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Harmine Induces Gastric Cancer Cell Apoptosis through the ROSmediated PI3K/AKT Signaling Pathway
Current Signal Transduction Therapy Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation
Anti-Cancer Agents in Medicinal Chemistry Pharmaceutical Nanotechnology United States Patent Watch (January – March 2016)
Pharmaceutical Nanotechnology Genome-wide Differential-based Analysis of the Relationship between DNA Methylation and Gene Expression in Cancer
Current Bioinformatics Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Fulvestrant - A Novel Endocrine Therapy for Breast Cancer
Current Medicinal Chemistry Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Interleukin-10
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Aberrant TGF-β Signaling in Pre-Clinical Models of Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Design of Potential Quinoxaline Anti-Infectives
Current Medicinal Chemistry